BioCryst, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Stacy Ku from TD Cowen maintained a Buy rating on the stock and has a $30.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Stacy Ku’s rating is based on the robust growth trajectory of BioCryst’s Orladeyo in the hereditary angioedema (HAE) market. The company’s third-quarter sales figures for Orladeyo reached approximately $159.1 million, demonstrating a 37% year-over-year increase and aligning with market expectations. This growth is attributed to steady patient accumulation, solid retention rates, and the addition of new prescribers, despite the presence of new injectable competitors. Management has also narrowed its 2025 sales guidance for Orladeyo to $590-600 million, reflecting a 36% increase, which underscores the drug’s strong market position.
Furthermore, BioCryst’s strategic initiatives, such as the proposed acquisition of ATXS, are expected to bolster Orladeyo’s momentum and solidify the company’s standing in the HAE market. The company’s valuation, trading at approximately 2x its estimated 2027 revenues, presents a value discount that investors should consider. Additionally, the long-term retention rate for Orladeyo is over 60%, providing a stable patient base. These factors, combined with positive key opinion leader (KOL) feedback and the potential market impact of navenibart, contribute to the Buy rating for BioCryst’s stock.
Based on the recent corporate insider activity of 35 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BCRX in relation to earlier this year.